Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). Patients and methods: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. Results: A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002). Conclusion: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) / Santoni, Matteo; Massari, Francesco; Myint, Zin W; Iacovelli, Roberto; Pichler, Martin; Basso, Umberto; Kopecky, Jindrich; Kucharz, Jakub; Buti, Sebastiano; Salfi, Alessia; Büttner, Thomas; De Giorgi, Ugo; Kanesvaran, Ravindran; Fiala, Ondřej; Grande, Enrique; Zucali, Paolo Andrea; Fornarini, Giuseppe; Bourlon, Maria T; Scagliarini, Sarah; Molina-Cerrillo, Javier; Aurilio, Gaetano; Matrana, Marc R; Pichler, Renate; Cattrini, Carlo; Büchler, Tomas; Seront, Emmanuel; Calabrò, Fabio; Pinto, Alvaro; Berardi, Rossana; Zgura, Anca; Mammone, Giulia; Ansari, Jawaher; Atzori, Francesco; Chiari, Rita; Zakopoulou, Roubini; Caffo, Orazio; Procopio, Giuseppe; Bassanelli, Maria; Zampiva, Ilaria; Messina, Carlo; Küronya, Zsófia; Mosca, Alessandra; Bhuva, Dipen; Vau, Nuno; Incorvaia, Lorena; Rebuzzi, Sara Elena; Roviello, Giandomenico; Zabalza, Ignacio Ortego; Rizzo, Alessandro; Mollica, Veronica; Catalini, Ilaria; Monteiro, Fernando Sabino M; Montironi, Rodolfo; Battelli, Nicola; Rizzo, Mimma; Porta, Camillo. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1938-0682. - (2023). [10.1016/j.clgc.2023.03.006]

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Buti, Sebastiano
Membro del Collaboration Group
;
2023-01-01

Abstract

Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). Patients and methods: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. Results: A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002). Conclusion: Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.
2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) / Santoni, Matteo; Massari, Francesco; Myint, Zin W; Iacovelli, Roberto; Pichler, Martin; Basso, Umberto; Kopecky, Jindrich; Kucharz, Jakub; Buti, Sebastiano; Salfi, Alessia; Büttner, Thomas; De Giorgi, Ugo; Kanesvaran, Ravindran; Fiala, Ondřej; Grande, Enrique; Zucali, Paolo Andrea; Fornarini, Giuseppe; Bourlon, Maria T; Scagliarini, Sarah; Molina-Cerrillo, Javier; Aurilio, Gaetano; Matrana, Marc R; Pichler, Renate; Cattrini, Carlo; Büchler, Tomas; Seront, Emmanuel; Calabrò, Fabio; Pinto, Alvaro; Berardi, Rossana; Zgura, Anca; Mammone, Giulia; Ansari, Jawaher; Atzori, Francesco; Chiari, Rita; Zakopoulou, Roubini; Caffo, Orazio; Procopio, Giuseppe; Bassanelli, Maria; Zampiva, Ilaria; Messina, Carlo; Küronya, Zsófia; Mosca, Alessandra; Bhuva, Dipen; Vau, Nuno; Incorvaia, Lorena; Rebuzzi, Sara Elena; Roviello, Giandomenico; Zabalza, Ignacio Ortego; Rizzo, Alessandro; Mollica, Veronica; Catalini, Ilaria; Monteiro, Fernando Sabino M; Montironi, Rodolfo; Battelli, Nicola; Rizzo, Mimma; Porta, Camillo. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1938-0682. - (2023). [10.1016/j.clgc.2023.03.006]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2944151
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact